Evotec SE (EVOTF) Income from Continuing Operations (2020 - 2025)
Evotec SE's (EVOTF) quarterly Income from Continuing Operations came in at 100864102.82 in Q4 2025, up 51.3% year-on-year from 66667101.08 in Q4 2024, and down 200734.07% quarter-over-quarter from 50222.61 in Q3 2025.
Evotec SE (EVOTF) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Evotec SE has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 100864102.82 for Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 100864102.82, up 51.3% year-over-year; the trailing twelve-month figure through Dec 2025 was 308058404.71 (down 3.6% YoY), and the FY2025 annual result was 120498292.51, up 42.49% from the prior year.
- Income from Continuing Operations came in at 100864102.82 for Q4 2025 at Evotec SE, down from 50222.61 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 246254632.58 in Q4 2021 to a low of 207092601.34 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 22254.35 (2023), against an average of 22075629.67.
- Across the five-year window, Income from Continuing Operations jumped 9714.16% in 2021 and tumbled 326.51% in 2024, its largest moves.
- Evotec SE's Income from Continuing Operations stood at 246254632.58 in 2021, then tumbled by 172.83% to 179338481.97 in 2022, then soared by 49.68% to 90236548.48 in 2023, then slumped by 129.5% to 207092601.34 in 2024, then surged by 51.3% to 100864102.82 in 2025.
- The last three Income from Continuing Operations figures came in at 100864102.82 (Q4 2025), 50222.61 (Q3 2025), and 207092601.34 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Evotec SE | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -100.86 Mn |
| Sep 30, 2025 | -50,222.61 |
| Dec 31, 2024 | -207.09 Mn |
| Sep 30, 2024 | -51,477.94 |
| Dec 31, 2023 | -90.24 Mn |
| Sep 30, 2023 | 22,726.50 |
| Jun 30, 2023 | -22,254.35 |
| Dec 31, 2022 | -179.34 Mn |
| Sep 30, 2022 | 39,779.45 |
| Jun 30, 2022 | -22,125.42 |
| Mar 31, 2022 | -72,868.90 |
| Dec 31, 2021 | 246.25 Mn |
| Sep 30, 2021 | 158,344.09 |
| Jun 30, 2021 | 72,202.09 |
| Mar 31, 2021 | 68,554.02 |
| Dec 31, 2020 | 7.48 Mn |
| Sep 30, 2020 | -1,646.99 |